Natixis Has $14.72 Million Stake in Humana Inc. (NYSE:HUM)

Natixis lowered its stake in shares of Humana Inc. (NYSE:HUM) by 68.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 58,013 shares of the insurance provider’s stock after selling 128,455 shares during the period. Natixis’ holdings in Humana were worth $14,718,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. FPC Investment Advisory Inc. acquired a new stake in shares of Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC acquired a new stake in Humana during the fourth quarter worth $30,000. LFA Lugano Financial Advisors SA boosted its stake in Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management bought a new stake in Humana in the 4th quarter valued at $33,000. Finally, Atwood & Palmer Inc. raised its stake in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

HUM stock opened at $264.41 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The business’s fifty day moving average is $265.90 and its 200-day moving average is $270.03. The company has a market cap of $31.91 billion, a P/E ratio of 26.57, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities research analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. Humana’s dividend payout ratio is currently 35.58%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Barclays upped their target price on shares of Humana from $270.00 to $322.00 and gave the company an “equal weight” rating in a research note on Friday, April 11th. Morgan Stanley lowered their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. Royal Bank of Canada reissued an “outperform” rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Finally, Robert W. Baird increased their target price on shares of Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 15th. Seventeen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $284.90.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.